BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
September 23, 2024 07:30 ET
|
Context Therapeutics Inc.
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and...
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
September 04, 2024 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
August 07, 2024 16:17 ET
|
Context Therapeutics Inc.
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 ...
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
August 01, 2024 07:30 ET
|
Context Therapeutics Inc.
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company’s two clinical-stage T cell...
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
July 10, 2024 07:30 ET
|
Context Therapeutics Inc.
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10,...
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 08, 2024 16:06 ET
|
Context Therapeutics Inc.
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE...
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
May 02, 2024 07:31 ET
|
Context Therapeutics Inc.
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) --...
Context Therapeutics Announces $100 Million Private Placement
May 02, 2024 07:30 ET
|
Context Therapeutics Inc.
Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 ...
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
April 01, 2024 07:30 ET
|
Context Therapeutics Inc.
PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
March 21, 2024 07:43 ET
|
Context Therapeutics Inc.
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into...